UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

 $(Amendment No. 1)^1$

Celldex Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value \$0.001 per share
(Title of Class of Securities)
15117B202
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
⊠ Rule 13d-1(c)
□ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, <i>see</i> the <i>Notes</i>).

1	NAME OF REPOR	TING PERSON	
	Riotechnolog	y Value Fund, L.P.	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		- 0 -	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		- 0 -	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		- 0 -	
	8	SHARED DISPOSITIVE POWER	
		- 0 -	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	- 0 -		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
12	0%		
12	TYPE OF REPORT	TING PERSON	
	PN		

1	NAME OF REPOR	TING PERSON	
1		III O I BROOM	
	BVF I GP LL	.C	
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
2	CEC LICE ONLY		
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
AHII (DED OF	Delaware	COLE VOTING POLITE	
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		- 0 -	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING PERSON WITH		- 0 -	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		- 0 -	
	8	SHARED DISPOSITIVE POWER	
9	ACCDECATE AM	- 0 - OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	- 0 -		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DEDCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
11	PERCENT OF CLA	ASS REPRESENTED BY AMIOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	TING PERSON	
	000		
	00		

1	NAME OF REPORT	TING PERSON	
	Biotechnology	Value Fund II, L.P.	
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	-
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER - 0 -	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER - 0 -	
PERSON WITH	7	SOLE DISPOSITIVE POWER - 0 -	
	8	SHARED DISPOSITIVE POWER - 0 -	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	- 0 -		
10	CHECK BOX IF TH	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
12	0%	INC PERCON	
12	TYPE OF REPORT	ING PERSUN	
	PN		

1	NAME OF REPOR	TING PERSON	
	BVF II GP LI	I.C	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		- 0 -	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		- 0 -	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	0	- 0 -	
	8	SHARED DISPOSITIVE POWER	
9	ACCDECATE AM	- 0 - OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	- 0 -	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П
10	CILCIO BOX II' II	TE AGGLEGITE AMOUNT IN NOW (3) EACEODES CENTAIN SHAKES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
		= = ===================================	
12	0% TYPE OF REPORT	TING PERSON	
	00		
	00		

1	NAME OF REPOR	RTING PERSON	
	Riotechnolog	gy Value Trading Fund OS LP	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) 🗆
3	SEC USE ONLY		
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Cayman Islaı	nds	
NUMBER OF	5	SOLE VOTING POWER	
SHARES BENEFICIALLY		- 0 -	
OWNED BY	6	SHARED VOTING POWER	
EACH REPORTING		- 0 -	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	8	- 0 - SHARED DISPOSITIVE POWER	
9	ACCRECATE AM	- 0 - OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
3	AGGREGATE ANY	OCIVI BENEFICINEEL OWNED BY ENGINEELOKIING LEKSON	
10	- 0 -	THE ACCRECATE AMOUNT IN DOM/O) EVOLUDES CERTAIN SHARES	П
10	CHECK BOX IF I	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	Ц
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	TING PERSON	
	PN		

1	NAME OF REPORT	TING PERSON	
	BVF Partners	OS Ltd.	
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Cayman Island		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER - 0 -	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER - 0 -	
PERSON WITH	7	SOLE DISPOSITIVE POWER - 0 -	
	8	SHARED DISPOSITIVE POWER - 0 -	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	- 0 -		
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	ING PERSON	
	CO		

1	NAME OF REPOR	TING PERSON	
	BVF GP HO	LDINGS LLC	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER	
PERSON WITH	7	SOLE DISPOSITIVE POWER - 0 -	
	8	SHARED DISPOSITIVE POWER	
9	AGGREGATE AM	- 0 - OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	- 0 -		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	TING PERSON	
	00		

1	NAME OF REPOR	TING PERSON	
	BVF Partners	; L.P.	
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	8	SHARED DISPOSITIVE POWER	
9	AGGREGATE AM	- 0 - OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
3	- 0 -	CONT BENEFICIALET OWNER BY ENGINEER ON THE OWNER OF THE OWNER BY	
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
- 12	0%	EING DEDGON	
12	TYPE OF REPORT	TING PERSON	
	PN, IA		

1	NAME OF REPOR	TING PERSON	
	BVF Inc.		
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
_		ROTHINE BOX II ATMEMBER OF A GROOT	(a) □ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	_		
NUMBER OF	Delaware	COLE VOTING DOMED	
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		- 0 -	
OWNED BY	6	SHARED VOTING POWER	
EACH REPORTING		- 0 -	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	,	0022 2101 00111 12 1 0 11211	
		- 0 -	
	8	SHARED DISPOSITIVE POWER	
		- 0 -	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	- 0 -		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
			_
- 11	DED CENT OF C	ACC DEPOSITION AND ANALYSIS IN POLICE	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	TING PERSON	
	60		
	CO		

	 		
1	NAME OF REPO	RTING PERSON	
	Mark N. Laı		
2	CHECK THE API	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OF	R PLACE OF ORGANIZATION	
	United State	S	
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		- 0 -	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		- 0 -	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		- 0 -	
	8	SHARED DISPOSITIVE POWER	
		- 0 -	
9	AGGREGATE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	- 0 -		
10	CHECK BOX IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)	
		、 /	
	0%		
12	TYPE OF REPOR	TING PERSON	
	IN		
<u> </u>	!		

Item 1(a). Name of Issuer:

Celldex Therapeutics, Inc., a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

Perryville III Building, 53 Frontage Road, Suite 220,

Hampton, New Jersey 08827

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF I GP LLC ("BVF GP") 44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF II GP LLC ("BVF2 GP")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH") 44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Inc.

44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.01 per share (the "Shares").

Item 2(e). CUSIP Number:

15117B202

Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment company registered under Section 8 of the Investment Company Act.
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	//	A church plan that is excluded from the definition of an investment company under Section $3(c)(14)$ of the Investment Company Act.
(j)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k)	//	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: $__$

Item 4. Ownership

As of the close of business on December 31, 2020, the Reporting Persons no longer beneficially owned any Shares of the Issuer.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or

Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on June 26, 2020.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

BVF Partners L.P., its sole member

BVF Inc., its general partner

/s/ Mark N. Lampert Mark N. Lampert President

By:

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2021 BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP By: BVF Partners L.P., its investment manager BVF I GP LLC., its general partner BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF I GP LLC BVF GP HOLDINGS LLC** /s/ Mark N. Lampert By: Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert Chief Executive Officer BIOTECHNOLOGY VALUE FUND II, L.P. BVF PARTNERS L.P. BVF II GP LLC, its general partner By: BVF Inc., its general partner /s/ Mark N. Lampert By: Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF II GP LLC** BVF INC. By: /s/ Mark N. Lampert By: /s/ Mark N. Lampert Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF PARTNERS OS LTD. /s/ Mark N. Lampert

MARK N. LAMPERT

16